Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Comorbid Conditions in CML

Researching conditions that affect TKI selection

Publish date:: October 7, 2015

The prevalence of relevant comorbid conditions is substantial among chronic myelogenous leukemia (CML) patients in the U.S. managed care setting, according to a study of 2,296 patients with CML who initiated treatment with a first-line tyrosine kinase inhibitor (TKI). Researchers found:

• Median age of the CML study population newly initiated on TKI treatment was 56 years.

• About 41% of the study population had at least 1 comorbid condition that could influence the choice of TKI treatment.

• Most prevalent comorbidities were heart disease (23%), diabetes (18%), and lung disease (13%).

• Prevalence of comorbidities relevant to TKI treatment choice varied among patients of different age groups, gender, and U.S. regions.

Citation: Jabbour E, Makenbaeva D, Longohr-Smith M, Lin J. Use of real-world claim databases to assess prevalence of comorbid conditions relevant to the treatment of chronic myelogenous leukemia based on National Comprehensive Network treatment guidelines. [Published online ahead of print September 29, 2015]. Clin Lymphoma Myeloma Leuk. doi: http://dx.doi.org/10.1016/j.clml.2015.09.008.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in CML

Survey quantifies COVID-19’s impact on oncology,

Baseline gene expression predicts TKI response in CML,

Inotuzumab/bosutinib treat R/R Ph+ ALL, CML in blast phase,

Complementary medicine use common among patients on TKIs,

Treatment-free remission in CML, Mahon FX et al. Ann Intern Med. 2018 Feb 20. doi: 10.7326/M17-1094.